Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2011

01-03-2011 | Review article

Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis

Authors: Rebecca Gilbert, Richard M. Martin, Rebecca Beynon, Ross Harris, Jelena Savovic, Luisa Zuccolo, Geertruida E. Bekkering, William D. Fraser, Jonathan A. C. Sterne, Chris Metcalfe

Published in: Cancer Causes & Control | Issue 3/2011

Login to get access

Abstract

Objective

We systematically reviewed and meta-analyzed literature examining associations of vitamin D (dietary intake, circulating 25-hydroxy-vitamin-D (25(OH)D), and 1,25-dihydroxy-vitamin-D (1,25(OH)2D) concentrations) with prostate cancer.

Methods

We searched over 24,000 papers from seven electronic databases (to October 2010) for exposures related to vitamin D. We conducted dose–response random-effects meta-analyses pooling the log odds ratio (OR) and 95% confidence intervals (CI) per change in natural units of each exposure. The I2 statistic quantified between-study variation due to heterogeneity.

Results

Twenty-five papers were included. In prospective studies, the OR per 1,000 IU increase in dietary intake was 1.14 (6 studies; CI: 0.99, 1.31; I 2 = 0%) for total prostate cancer and 0.93 (3 studies; 0.63, 1.39; I 2 = 25%) for aggressive prostate cancer. Five case–control studies examined dietary intake, but there was a high degree of inconsistency between studies (I 2 = 49%). The OR per 10 ng/mL increase in 25(OH)D was 1.04 (14 studies; 0.99, 1.10; I 2 = 0%) for total prostate cancer and 0.98 (6 studies; 0.84, 1.15; I 2 = 32%) for aggressive prostate cancer. The OR per 10 pg/mL increase in 1,25(OH)2D was 1.00 (7 studies; 0.87, 1.14; I 2 = 41%) for total prostate cancer and 0.86 (2 studies; 0.72, 1.02; I 2 = 0%) for aggressive prostate cancer.

Conclusion

Published literature provides little evidence to support a major role of vitamin D in preventing prostate cancer or its progression.
Appendix
Available only for authorised users
Literature
1.
Cancer Research UK (2008) Commonly diagnosed cancers worldwide
2.
Cancer Research UK (2008) CancerStats report Prostate Cancer—UK, Cancer Research UK
3.
Office for National Statistics (2007) Cancer incidence and mortality in the United Kingdom 2002–2004. Office for National Statistics
4.
Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiol Rev 78(4):1193–1231PubMed
5.
Chen TC, Holick MF (2003) Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metabol 14(9):423–430CrossRef
6.
Gilbert R, Metcalfe C, Oliver SE et al (2009) Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. Int J Cancer 125(6):1414–1423CrossRefPubMed
7.
Tuohimaa P, Tenkanen L, Ahonen M et al (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108:104–108CrossRefPubMed
8.
9.
10.
Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10(2):131–140CrossRefPubMed
11.
Young MV, Schwartz GG, Wang L et al (2004) The prostate 25-hydroxyvitamin D-1{alpha}-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25(6):967–971CrossRefPubMed
12.
Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF (2003) Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 88(2):315–322CrossRefPubMed
13.
Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16(2):83–95CrossRefPubMed
14.
Gross MD (2005) Vitamin D and calcium in the prevention of prostate and colon cancer: new approaches for the identification of needs. J Nutr 135(2):326–331PubMed
15.
World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC
16.
Yin L, Raum E, Haug U, Arndt V, Brenner H (2009) Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol 33:435–445CrossRefPubMed
17.
Chene G, Thompson SG (1996) Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form. Am J Epidemiol 144(6):610–621PubMed
18.
Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135(11):1301–1309PubMed
19.
Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM (2009) Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer 124(10):2416–2429CrossRefPubMed
20.
Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord R, Sterne JAC (2008) Metan: fixed- and random-effects meta-analysis. Stata J 8(1):3–28
21.
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560CrossRefPubMed
22.
Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT (1997) A case-control study of diet and prostate cancer. Br J Cancer 76(5):678–687CrossRefPubMed
23.
Vlajinac HD, Marinkovic JM, Ilic MD, Kocev NI (1997) Diet and prostate cancer: a case-control study. Eur J Cancer 33(1):101–107CrossRefPubMed
24.
Deneo-Pellegrini H, De Stefani E, Ronco A, Mendilaharsu M (1999) Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br J Cancer 80(3–4):591–597CrossRefPubMed
25.
Chan JM, Pietinen P, Virtanen M et al (2000) Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 11(9):859–867CrossRefPubMed
26.
Berndt SI, Carter HB, Landis PK et al (2002) Calcium intake and prostate cancer risk in a long-term aging study: the baltimore longitudinal study of aging. Urology 60(6):1118–1123CrossRefPubMed
27.
Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E (2004) Plasma 1, 25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15(3):255–265CrossRefPubMed
28.
Tavani A, Bertuccio P, Bosetti C et al (2005) Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 48(1):27–33CrossRefPubMed
29.
Tseng M, Breslow RA, Graubard BI, Ziegler RG (2005) Dairy, calcium, and vitamin D intakes and prostate cancer risk in the national health and nutrition examination epidemiologic follow-up study cohort. Am J Clin Nutr 81(5):1147–1154PubMed
30.
Park SY, Murphy SP, Wilkens LR, Stram DO, Henderson BE, Kolonel LN (2007) Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 166(11):1259–1269CrossRefPubMed
31.
Ahn J, Peters U, Albanes D et al (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100(11):796–804CrossRefPubMed
32.
Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL (2009) Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomark Prev 18(6):1929–1933CrossRef
33.
Kristal AR, Cohen JH, Qu P, Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomark Prev 11(8):719–725
34.
Kristal AR, Arnold KB, Neuhouser ML et al (2010) Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial. Am J Epidemiol 172(5):566–577CrossRefPubMed
35.
Corder EH, Guess HA, Hulka BS et al (1993) Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev 2(5):467–472
36.
Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6(3):235–239CrossRefPubMed
37.
Nomura AM, Stemmermann GN, Lee J et al (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4):425–432CrossRefPubMed
38.
Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1, 25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89–90(1–5):533–537CrossRefPubMed
39.
Baron JA, Beach M, Wallace K et al (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomark Prev 14(3):586–589CrossRef
40.
Li H, Stampfer MJ, Hollis JB et al (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med Public Libr Sci 4(3):e103
41.
Faupel-Badger JM, Diaw L, Albanes D, Virtamo J, Woodson K, Tangrea JA (2007) Lack of association between serum levels of 25-Hydroxyvitamin D and the subsequent risk of prostate cancer in finnish men. Cancer Epidemiol Biomark Prev 16(12):2784–2786CrossRef
42.
Freedman DM, Looker AC, Chang SC, Graubard BI (2007) Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99(21):1594–1602CrossRefPubMed
43.
Travis RC, Crowe FL, Allen NE et al (2009) Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European prospective investigation into cancer and nutrition (EPIC). Am J Epidemiol 169(10):1223–1232CrossRefPubMed
44.
Barnett CM, Nielson CM, Shannon J et al. (2010) Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes and Control online
45.
Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN (2010) Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 46(5):932–936CrossRefPubMed
46.
Bates B, Lennox A, Swan G (2010) National diet and nutrition survey: headline results from year 1 of the rolling programme (2008/2009). Food Standards Agency, Department of Health, London
47.
Ruston D, Henderson L, Gregory J et al. (2004) The national diet and nutrition survey: adults aged 19–64 years. Volume 4: nutritional status (anthropometry and blood analytes), blood pressure and physical activity. TSO, London
48.
Chen L, Davey SG, Evans DM et al (2009) Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomark Prev 18(11):2874–2881CrossRef
49.
Egger M, Schneider M, Davey SG (1998) Spurious precision? Meta-analysis of observational studies. BMJ 316(7125):140–144PubMed
50.
Bekkering GE, Harris RJ, Thomas S et al (2008) How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis? Am J Epidemiol 167(9):1017–1026CrossRefPubMed
51.
Ahn J, Albanes D, Peters U et al (2007) Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev 16(12):2623–2630CrossRef
52.
Giovannucci E, Rimm EB, Wolk A et al (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58(3):442–447PubMed
53.
Galic J, Simunovic D (2008) Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia. Coll Antropol 32(4):1195–1202PubMed
54.
Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A (1998) Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control 9(6):559–566CrossRefPubMed
55.
Rodriguez C, McCullough ML, Mondul AM et al (2003) Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomark Prev 12(7):597–603
56.
Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11(9):847–852CrossRefPubMed
57.
Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomark Prev 5(2):121–126
58.
Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67(9):911–923CrossRefPubMed
59.
Tuohimaa P, Tenkanen L, Syvala H et al (2007) Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomark Prev 16(2):302–307CrossRef
60.
Polek TC, Weigel NL (2002) Vitamin D and prostate cancer. J Androl 23(1):9–17PubMed
61.
Gao X, LaValley MP, Tucker KL (2005) Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. J Natl Cancer Inst 97(23):1768–1777CrossRefPubMed
62.
Calvo MS, Whiting SJ, Barton CN (2005) Vitamin D intake: a global perspective of current status. J Nutr 135(2):310–316PubMed
63.
Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF (1999) Vitamin A antagonizes the action of vitamin D in rats. J Nutr 129(12):2246–2250PubMed
64.
Bodnar LM, Catov JM, Wisner KL, Klebanoff MA (2009) Racial and seasonal differences in 25-hydroxyvitamin D detected in maternal sera frozen for over 40 years. Br J Nutr 101:278–284CrossRefPubMed
65.
Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D (2004) Prostate-specific antigen test use reported in the 2000 national health interview survey. Prev Med 38(6):732–744CrossRefPubMed
66.
Weinrich S, Ellison G, Weinrich M, Ross KS, Reis-Starr C (2002) Low sun exposure and elevated serum prostate specific antigen in African American and Caucasian men. Am J Health Stud 17:148–150
67.
Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1, 25-dihydroxyvitamin D3 (calcitriol). J Urol 159(6):2035–2039CrossRefPubMed
68.
Huncharek M, Muscat J, Kupelnick B (2008) Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26, 769 cases from 45 observational studies. Nutr Cancer 60(4):421–441CrossRefPubMed
69.
Gupta D, Lammersfeld CA, Trukova K, Lis CG (2009) Vitamin D and prostate cancer risk: a review of the epidemiological literature. Prostate Cancer Prostatic Dis 12(3):215–226CrossRefPubMed
70.
Gandini S, Boniol M, Haukka J et al. (2010) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. doi:10.​1002/​ijc.​25439
Metadata
Title
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
Authors
Rebecca Gilbert
Richard M. Martin
Rebecca Beynon
Ross Harris
Jelena Savovic
Luisa Zuccolo
Geertruida E. Bekkering
William D. Fraser
Jonathan A. C. Sterne
Chris Metcalfe
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 3/2011
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9706-3

Other articles of this Issue 3/2011

Cancer Causes & Control 3/2011 Go to the issue

Review article

Inequity in access to cancer care: a review of the Canadian literature

Original paper

Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study

Original paper

Physical activity, additional breast cancer events, and mortality among early-stage breast cancer survivors: findings from the WHEL Study

Original paper

Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study

Brief report

Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?

Original paper

The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits